- Conditions
- Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
- Interventions
- ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 93
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Graft-Versus-Host Disease (GVHD) Acute on Chronic
- Interventions
- Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- rAAV1-CB-hAAT
- Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Worcester, Massachusetts • Cincinnati, Ohio
- Conditions
- Graft vs Host Disease
- Interventions
- Alpha-1-Antitrypsin (AAT)
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Neuromyelitis Optica
- Interventions
- Alpha1-antitrypsin, methylprednisolone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Alpha1-antitrypsin Deficiency
- Interventions
- GLASSIA
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- Alpha-1 antitrypsin (AAT), Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more
- Conditions
- Alpha-1 Antitrypsin Deficiency, Emphysema, Chronic Obstructive Pulmonary Disease
- Interventions
- Aspirin, Placebo, Withdrawal from alpha1 antitrypsin replacement therapy
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Aralast NP, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 10 more
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
- Interventions
- Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
- Procedure · Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
- Interventions
- History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
- Procedure · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2033
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pulmonary Emphysema in Alpha-1 PI Deficiency
- Interventions
- Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
- Biological · Other
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- rAAV1-CB-hAAT
- Biological
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Worcester, Massachusetts
- Conditions
- Alpha₁-Antitrypsin Deficiency
- Interventions
- Liquid Alpha₁-PI, Prolastin-C
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- BEAM-302
- Drug
- Lead sponsor
- Beam Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Charleston, South Carolina
- Conditions
- Kidney Transplant, Type 1 Diabetes
- Interventions
- Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- VX-864
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Gainesville, Florida • Orlando, Florida • Iowa City, Iowa + 7 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- 4-PBA
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Lung Cancer, Bilateral Cancer, Lung Transplant
- Interventions
- Double Lung Transplantation
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- No Intervention
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Charleston, South Carolina
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Interventions
- Liver Biopsy (Biopsy Group Only)
- Procedure
- Lead sponsor
- St. Louis University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 3
- States / cities
- San Diego, California • Boston, Massachusetts • St Louis, Missouri
- Conditions
- Alpha-1 Antitrypsin Deficiency, AATD
- Interventions
- INBRX-101/rhAAT-Fc
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Alpha1-antitrypsin Deficiency, Healthy Volunteers
- Interventions
- Alpha1-proteinase inhibitor, Placebo: Human albumin 2.5%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas